All Stories

  1. One Month Versus Three Months of Aspirin After Percutaneous Coronary Intervention: A Reconstructed Time-to-Event Analysis
  2. Incidence of left ventricular thrombus and subclinical cerebral infarction by magnetic resonance imaging 2 weeks after anterior ST-elevation myocardial infarction with impaired left ventricular function and apical akinesis
  3. Geographic heterogeneity in outcomes of intravascular ultrasound-guided vs angiography-guided percutaneous coronary intervention: a meta-analysis of randomized trials
  4. Impact of Left Ventricular Unloading on Hemodynamics and Stunning in Complex PCI
  5. The Molecular Footprint of Thrombosis: What Does Myocardial Platelet Imaging After STEMI Tell Us?
  6. Reperfusion Injury and Infarct Size: Why Translation has Been Difficult, and How We Move Forward
  7. Smartwatch and Wearable Detection of Atrial Fibrillation: Current Evidence and Clinical Implications
  8. A Mandated Risk Score Meets Real-World Destination Therapy
  9. Racial and ethnic disparities in percutaneous coronary intervention: contemporary evidence and pathways to equity
  10. Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year
  11. Is Aspirin Still Indispensable After PCI—Rethinking Dual Antiplatelet Therapy in Contemporary Practice
  12. Oxidative dyslipidemia in early pregnancy: integrating atherogenic index of plasma (AIP) and uric acid (UA) to refine preeclampsia risk stratification
  13. Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs
  14. Impact of Coronary Function Testing on Symptoms and Quality of Life in Patients with Coronary Microvascular Dysfunction: Meta-Analysis of Randomised Controlled Trials
  15. An Updated Meta-Analysis of Randomized Controlled Trials Comparing Direct Oral Anticoagulants Against Warfarin for Left Ventricular Thrombus Resolution
  16. Response by Bulluck and Hausenloy to Letter Regarding Article, “Effect of Cangrelor on Infarct Size in ST-Segment–Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (the PITRI Trial)”
  17. Radiological abnormalities persist following COVID-19 and correlate with impaired health-related quality of life: a prospective cohort study of hospitalised patients
  18. Letter to the Editor Regarding “A Meta-Analysis of RCTs Comparing DOACs Against Warfarin for the Treatment of Left Ventricular Thrombus”
  19. A meta-analysis of randomised controlled trials comparing optical coherence tomography-guided against angiography-guided revascularisation
  20. Effect of Cangrelor on Infarct Size in ST-Segment–Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)
  21. Prognostic Significance of Peri-Infarct Ischemia
  22. Therapeutic hypothermia to reduce infarct size in STEMI: time to give it the cold shoulder?
  23. 38 A meta-analysis of randomised controlled trials comparing direct oral anticoagulants against warfarin for the treatment left ventricular thrombus
  24. 50 A meta-analysis of randomised controlled trials comparing optical coherence tomography-guided against angiography-guided revascularisation
  25. Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization
  26. Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study
  27. Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention on Medium-Term Outcomes: A Contemporary Meta-Analysis of Randomized Controlled Trials
  28. Follow-up optical coherence tomography to evaluate circumflex ostium after fenestration of left main Papyrus covered stent: a case report
  29. Post-COVID-19 illness and associations with sex and gender
  30. A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice
  31. Defining Peri-Operative Myocardial Injury during Cardiac Surgery Using High-Sensitivity Troponin T
  32. Association of body mass index, metabolic health status and clinical outcomes in acute myocardial infarction patients: a national registry-based study
  33. Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19
  34. Optimising patient selection for CTO PCI – The PICA approach
  35. Meta-Analysis Comparing Clinical Outcomes of Fractional-Flow-Reserve- and Angiography-Guided Multivessel Percutaneous Coronary Intervention
  36. Fractional Flow Reserve versus Angiography–Guided Management of Coronary Artery Disease: A Meta–Analysis of Contemporary Randomised Controlled Trials
  37. Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials
  38. TCT-269 FFR-Guided Versus Angiography-Guided PCI in Multivessel Coronary Artery Disease: A Meta-Analysis of RCTs
  39. Comparison of the modified Singapore myocardial infarction registry risk score with GRACE 2.0 in predicting 1-year acute myocardial infarction outcomes
  40. Meta-Analysis Comparing 10-Year Mortality Following Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in Left Main Stem or Multivessel Coronary Artery Disease
  41. Management of ST segment elevation myocardial infarction
  42. Negative interaction between nitrates and remote ischemic preconditioning in patients undergoing cardiac surgery: the ERIC-GTN and ERICCA studies
  43. 157 Multi-system investigation of covid-19 illness
  44. A multisystem, cardio-renal investigation of post-COVID-19 illness
  45. Comparison of Mortality Outcomes in Acute Myocardial Infarction Patients With or Without Standard Modifiable Cardiovascular Risk Factors
  46. Incidence and Clinical Predictors of Non-Obstructive Coronary Arteries in Patients With Suspected Non-ST Elevation Myocardial Infarction Undergoing Invasive Coronary Angiography
  47. A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction
  48. Contemporary tools and devices for coronary calcium modification
  49. Prognostically relevant cardiac troponin elevations with percutaneous coronary interventions
  50. Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients
  51. Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy
  52. Combining Invasive Coronary Physiology With CMR for Long-Term Risk-Stratification in STEMI
  53. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiov...
  54. Association between smoking status and outcomes in myocardial infarction patients undergoing percutaneous coronary intervention
  55. T and Small Protrusion (TAP) vs Double-Kissing Crush Technique: Insights From In Vitro Models
  56. Corrigendum to: Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data
  57. Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data
  58. Response to the letter to the editor regarding the study “Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality” published in the American Heart Journal
  59. Effect of remote ischemic preConditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial
  60. Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
  61. Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment–Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis
  62. Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality
  63. The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry
  64. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease
  65. Periprocedural elevated myocardial biomarkers and clinical outcomes following elective percutaneous coronary intervention: a comprehensive dose-response meta-analysis of 44,972 patients from 24 prospective studies
  66. Chronic myocardial edema in Fabry disease is linked to myocardial injury and left ventricular volume/pressure overload
  67. Periprocedural Cardiac Troponin and Mortality in Stable Patients Undergoing PCI
  68. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial
  69. A Multicenter, Scan-Rescan, Human and Machine Learning CMR Study to Test Generalizability and Precision in Imaging Biomarker Analysis
  70. The Effect of Blood Composition on T1 Mapping
  71. Toward Improving Our Understanding of the Relationship Between IMR and MVO in STEMI Patients
  72. Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention
  73. Optimized Treatment of ST-Elevation Myocardial Infarction
  74. Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients
  75. Feasibility to Perform T 2 * Mapping Postcontrast Administration in Reperfused STEMI Patients for the Detection of Intramyocardial Hemorrhage
  76. Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
  77. Defining a ‘frequent admitter’ phenotype among patients with repeat heart failure admissions
  78. Platelet Inhibition to Target Reperfusion Injury (The PITRI trial): Rationale and Study Design
  79. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis
  80. Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective
  81. Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era
  82. Modulating NAD+ metabolism to prevent acute kidney injury
  83. Management of ST segment elevation myocardial infarction
  84. Risk Stratification by Cardiovascular Magnetic Resonance After Reperfused ST-Segment Elevation Myocardial Infarction
  85. Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI
  86. Myocardial Edema and Prognosis in Amyloidosis
  87. Percutaneous coronary intervention of saphenous vein grafts: where do we stand?
  88. Cardiovascular Magnetic Resonance in Acute ST-Segment–Elevation Myocardial Infarction
  89. Letter by Bulluck and Hausenloy Regarding Article, “Dynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvage”
  90. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles
  91. Myocardial native T1 and extracellular volume with healthy ageing and gender
  92. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
  93. Fundamentals of bioresorbable stents
  94. Bioresorbable Scaffold Stability and Mechanical Properties
  95. Left Ventricular Hypertrophy Revisited
  96. Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes
  97. Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction
  98. 57 The effect of remote ischemic conditioning and glyceryl trinitrate on perioperative myocardial injury in cardiac bypass surgery patients: the eric-gtn study
  99. Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
  100. Response by Andrews et al to Letter Regarding Article, “Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging”
  101. Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality
  102. Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping
  103. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery
  104. Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T1 and T2 mapping
  105. Mapping Myocardial Salvage Index by Extracellular Volume Fraction
  106. Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging
  107. Magnetic Resonance in Transthyretin Cardiac Amyloidosis
  108. Quantifying the area-at-risk of myocardial infarction in-vivo using arterial spin labeling cardiac magnetic resonance
  109. Reply to “Circadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nuclei”
  110. 024 Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis
  111. 001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis
  112. Age and Surgical Complexity impact on Renoprotection by Remote Ischemic Preconditioning during Adult Cardiac Surgery: A Meta analysis
  113. Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance
  114. Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients
  115. Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies
  116. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment–Elevation Myocardial Infarction Patients
  117. Diagnostic performance of T 1 and T 2 mapping to detect intramyocardial hemorrhage in reperfused ST-segment elevation myocardial infarction (STEMI) patients
  118. Reply
  119. Bioresorbable stents: Current and upcoming bioresorbable technologies
  120. Gender Differences in Native Myocardial T1 in a Healthy Chinese Volunteer Cohort
  121. Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance
  122. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy
  123. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”
  124. Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment–Elevation Myocardial Infarction and Adverse Left Ventricular RemodelingCLINICAL PERSPECTIVE
  125. Index of Microvascular Resistance and Microvascular Obstruction in Patients With Acute Myocardial Infarction
  126. Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy
  127. Optimization of coronary optical coherence tomography imaging using the attenuation-compensated technique: a validation study
  128. Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction
  129. ORAL AB II QUICK FIRE BASIC1393Validation of aortic in-vitro strain measurement by Magnetic Resonance Imaging with realistic abdominal aortic aneurism phantom1474A novel method of Segment Length Tracking providing regional strain measures from standard...
  130. MODERATED EPOSTERS1385Longitudinal strain assessment in dilated cardiomyopathy patients using a novel accelerated DENSE sequence1407Simultaneous T1 and T2 cardiac quantification with CABIRIA: initial clinical experience1423Head-to-head comparison of ac...
  131. Response to Letters Regarding Article, “Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis”
  132. Quantifying the Area at Risk in Reperfused ST-Segment–Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomography–Magnetic Resonance ImagingCLINICAL PERSPECTIVE
  133. Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy
  134. Letter by Bulluck and Hausenloy Regarding Article, “Air Versus Oxygen in ST-Segment–Elevation Myocardial Infarction”
  135. High-sensitivity Troponin-T levels in reperfused STEMI patients: A comparison with CMR
  136. Chronic iron deposit and left ventricular remodeling in reperfused STEMI patients
  137. Left ventricular remodeling after reperfused acute myocardial infarction: insights from automated ECV mapping
  138. Automatic Measurement of the Myocardial Interstitium
  139. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials
  140. Remote Ischemic Preconditioning: Would You Give Your Right Arm to Protect Your Kidneys?
  141. CMR findings in high endurance veteran athletes - a 247 subject study
  142. Diffuse myocardial fibrosis - a therapeutic target? Proof of regression at 1-year following aortic valve replacement: the RELIEF-AS study
  143. ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
  144. Hematocrit, iron and HDL-cholesterol explain 90% of variation in native blood T1
  145. Native myocardial T1 and ECV with age and gender developing normal reference ranges - a 94 healthy volunteer study
  146. Reproducibility of native T1 mapping using ShMOLLI and MOLLI - implications for sample size calculation
  147. The Right ventricle and cardiac surgery - more resilient than thought: multiparametric quantification shows altered rather than reduced function
  148. Reducing myocardial infarct size: challenges and future opportunities
  149. Microvascular Obstruction: The Bane of Myocardial Reperfusion
  150. Obstrucción microvascular: el azote de la reperfusión miocárdica
  151. The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the ERIC-GTN Study
  152. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac AmyloidosisCLINICAL PERSPECTIVE
  153. T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients
  154. CardioPulse ArticlesEditors' network of the European Society of Cardiology National Cardiovascular Journals: scientific input from the National SocietiesHand grip strength predicts myocardial infarction and strokeEffect of remote ischaemic conditioning...
  155. Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis
  156. Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design
  157. Ischaemic conditioning: are we there yet?
  158. 29 Synthetic ECV – simplifying ECV quantification by deriving haematocrit from T1 blood
  159. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials
  160. An instantaneous ECV with no blood sampling: using native blood T1 for hematocrit is as good as standard ECV
  161. Clinical application of MOLLI T1* for extracellular volume calculation in healthy volunteers and aortic stenosis
  162. Hybrid PET/MR metabolic imaging of the reperfused infarct - new biology, future directions
  163. Incidence of left ventricular thrombi in reperfused STEMI patients detected by contrast-enhanced CMR
  164. LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study
  165. Myocardial T1 Mapping
  166. Myocardial iron quantification using T2* and native T1mapping - a 250 patient study
  167. Performance of automated ECV maps versus conventionally calculated ECV
  168. Precision and reproducibility of blood T1 estimation: implications of T1 star on ECV calculation
  169. Quantification of the area-at-risk by T1 and T2 mapping CMR at 3T
  170. A simple technique to measure TAPSE and MAPSE on CMR and normal values
  171. AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
  172. Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
  173. CMR detects a reduction in infarct size and myocardial edema when primary PCI is augmented by Remote Ischemic Conditioning. A randomized trial
  174. 045 PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST ELEVATION MYOCARDIAL INFARCTION: DOES DIRECT STENTING IMPACT ON MORTALITY?
  175. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk)
  176. S1238 Serum Lipids and the Risk of Developing Symptomatic Gallstones: A UK Prospective Cohort Study
  177. OC-030 Serum lipids and the risk of developing symptomatic gallstones: a UK prospective cohort study
  178. 14 Body Mass Index and the Risk of Symptomatic Gallstones - A Prospective Cohort Study in a UK Population
  179. 15 Alcohol Intake and Development of Symptomatic Gallstones: An Inverse Association - A UK Prospective Cohort Study